Literature DB >> 6809821

Phenotypic characteristics of cell lines requiring interleukin 3 for growth.

J N Ihle, J Keller, J S Greenberger, L Henderson, R A Yetter, H C Morse.   

Abstract

A number of cell lines have been derived from bone marrow cultures in the presence of WEHI-3 conditioned media (CM) that continue to require WEHI-3 CM for growth in vitro. Because the WEHI-3 cell line has been shown to constitutively produce a lymphokine (IL 3) that induces the expression of 20 alpha-hydroxysteroid dehydrogenase (20 alpha SDH) in cultures of splenic lymphocytes from athymic mice, we examined whether these cell lines were dependent upon IL 3 for growth. The results demonstrate that the factor required for growth of these cell lines copurifies with IL 3 activity on G-100, DEAE cellulose, and CM cellulose column chromatography as well as in preparative isoelectric focusing and on hydrophobic supports in reverse phase high pressure liquid chromatography. The biologic activity of peak fractions in each case was similar in both types of assays. These results strongly suggest that the WEHI-3 CM-dependent cell lines are dependent on IL 3 for growth in vitro. All the cell lines have readily detectable levels of 20 alpha SDH but have differing cell surface phenotypes. The C3HSFFV line is devoid of conventional lymphoid cell surface markers with the exception of Lyt-1, whereas the FDC-P1 expresses Thy-1, Ly-5, and H-11. Other cell lines have intermediate phenotypes.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6809821

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  Major histocompatibility complex determinants select T-cell receptor alpha chain variable region dominance in a peptide-specific response.

Authors:  K Natarajan; D Burstyn; M Zauderer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

2.  Identification of a common ecotropic viral integration site, Evi-1, in the DNA of AKXD murine myeloid tumors.

Authors:  M L Mucenski; B A Taylor; J N Ihle; J W Hartley; H C Morse; N A Jenkins; N G Copeland
Journal:  Mol Cell Biol       Date:  1988-01       Impact factor: 4.272

3.  GATA-1 dominantly activates a program of erythroid gene expression in factor-dependent myeloid FDCW2 cells.

Authors:  D Seshasayee; P Gaines; D M Wojchowski
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

4.  Truncation of the c-myb gene by a retroviral integration in an interleukin 3-dependent myeloid leukemia cell line.

Authors:  Y Weinstein; J N Ihle; S Lavu; E P Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

5.  Production of a T-cell hybrid producing a lymphokine stimulating eosinophil differentiation.

Authors:  D J Warren; C J Sanderson
Journal:  Immunology       Date:  1985-04       Impact factor: 7.397

6.  Antigen-specific T-cell lines transfer protective immunity against Trichinella spiralis in vivo.

Authors:  J Riedlinger; R K Grencis; D Wakelin
Journal:  Immunology       Date:  1986-05       Impact factor: 7.397

7.  Characterization of membrane homing receptors in two cloned murine hemopoietic progenitor cell lines.

Authors:  T Matsuoka; C Hardy; M Tavassoli
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

8.  Genetic control of eosinophilia. Analysis of production and response to eosinophil-differentiating factor in strains of mice infected with Trichinella spiralis.

Authors:  D A Lammas; L A Mitchell; D Wakelin
Journal:  Clin Exp Immunol       Date:  1989-07       Impact factor: 4.330

9.  Interleukin 3 binds to a 140-kDa phosphotyrosine-containing cell surface protein.

Authors:  R J Isfort; D Stevens; W S May; J N Ihle
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

10.  Retroviral insertions 90 kilobases proximal to the Evi-1 myeloid transforming gene activate transcription from the normal promoter.

Authors:  C Bartholomew; J N Ihle
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.